Calgary, Alberta–(Newsfile Corp. – August 30, 2021) – EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) (“EnerSpar” or the “Company“) and Nurexone Biologic Ltd. (“Nurexone“) are pleased to announce that they have entered an arms-length letter of intent dated 23 August 2021 (amended) pursuant to which EnerSpar and Nurexone propose to complete a business combination (the “Proposed Transaction“). read more